Anterior Gradient-2 monoclonal antibody inhibits lung cancer growth and metastasis by upregulating p53 pathway and without exerting any toxicological effects: A preclinical study
- 1 May 2019
- journal article
- research article
- Published by Elsevier in Cancer Letters
- Vol. 449, 125-134
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81373319, 81872790)
- Shanghai Science and Technology Commission Foundation (14431903400)
- Shanghai International Science and Technology Cooperation (184907411400)
This publication has 45 references indexed in Scilit:
- The estrogen-regulated anterior gradient 2 (AGR2) protein in breast cancer: a potential drug target and biomarkerBreast Cancer Research, 2013
- AGR2 Gene Function Requires a Unique Endoplasmic Reticulum Localization MotifJournal of Biological Chemistry, 2012
- Use of the mouse aortic ring assay to study angiogenesisNature Protocols, 2011
- AGR2 Is a Novel Surface Antigen That Promotes the Dissemination of Pancreatic Cancer Cells through Regulation of Cathepsins B and DCancer Research, 2011
- Anterior gradient 2: A novel player in tumor cell biologyCancer Letters, 2011
- Increased Expression of P-Glycoprotein Is Associated with Doxorubicin Chemoresistance in the Metastatic 4T1 Breast Cancer ModelThe American Journal of Pathology, 2011
- The protein disulfide isomerase AGR2 is essential for production of intestinal mucusProceedings of the National Academy of Sciences, 2009
- Significance of the metastasis-inducing protein AGR2 for outcome in hormonally treated breast cancer patientsBritish Journal of Cancer, 2006
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Multi-faceted analyses of a highly metastatic human lung cancer cell line NCI-H460-LNM35 suggest mimicry of inflammatory cells in metastasisOncogene, 2001